Profile data is unavailable for this security.
About the company
Sichuan Biokin Pharmaceutical Co Ltd is a China-based company mainly engaged in drug research and development, production and marketing. The Company is mainly engaged in two business sectors: chemical preparations and Chinese patent medicine preparations, and innovative biological medicine business. The Company's main products include propofol emulsion injection, dexmedetomidine hydrochloride injection, medium/long chain fat emulsion injection, ribavirin granules and other chemical preparations, Chaihuang granules and other Chinese patent medicine preparations. The Company mainly conducts its business in the domestic market.
- Revenue in CNY (TTM)5.90bn
- Net income in CNY4.39bn
- Incorporated2006
- Employees2.09k
- LocationSichuan Biokin Pharmaceutical Co LtdBaili Road, Strait LiangAn Science ParkCHENGDU 611130ChinaCHN
- Phone+86 2 885321013
- Fax+86 2 885320270
- Websitehttp://www.baili-pharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Tiantan Biological Products Corp | 5.11bn | 1.16bn | 49.08bn | 4.86k | 35.12 | 4.03 | -- | 9.60 | 0.7068 | 0.7068 | 3.10 | 6.15 | 0.3611 | 0.9104 | 171.46 | 1,051,960.00 | 11.18 | 11.71 | 16.00 | 16.50 | 52.26 | 49.39 | 30.97 | 27.71 | 3.41 | -- | 0.0094 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 33.99 |
| Shanghai Fosun Pharmaceutical (Group) | 40.69bn | 2.01bn | 54.43bn | 40.37k | 29.84 | 1.29 | -- | 1.34 | 0.7525 | 0.7525 | 15.24 | 17.36 | 0.368 | 2.90 | 5.28 | 1,007,829.00 | 2.32 | 4.31 | 3.83 | 7.01 | 46.73 | 50.71 | 6.31 | 10.65 | 0.79 | -- | 0.3818 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Beijing Tongrentang Co Ltd | 17.99bn | 1.72bn | 56.09bn | 16.78k | 32.59 | 4.13 | -- | 3.12 | 1.26 | 1.26 | 13.11 | 9.90 | 0.6079 | 1.23 | 10.82 | 1,072,010.00 | 8.84 | 8.20 | 16.50 | 16.17 | 45.32 | 46.59 | 14.55 | 13.33 | 2.28 | -- | 0.1632 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Sichuan Biokin Pharmaceutical Co Ltd | 5.90bn | 4.39bn | 77.67bn | 2.09k | 17.69 | 15.07 | -- | 13.16 | 10.95 | 10.95 | 14.71 | 12.86 | 1.37 | 1.85 | 41.29 | 2,828,652.00 | 102.16 | -- | 138.88 | -- | 95.70 | -- | 74.42 | -- | 3.75 | 828.87 | 0.1314 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 3.38bn | 128.47m | 83.79bn | 3.84k | 708.07 | 6.53 | -- | 24.81 | 0.0933 | 0.0933 | 2.68 | 10.12 | 0.2058 | 0.8371 | 0.8434 | 878,660.70 | 0.7531 | 24.08 | 0.9228 | 31.80 | 76.97 | 85.18 | 3.66 | 34.95 | 3.84 | -- | 0.0258 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| WuXi AppTec Co Ltd | 39.36bn | 9.38bn | 113.20bn | 41.12k | 12.72 | 2.13 | -- | 2.88 | 3.18 | 3.18 | 13.33 | 18.97 | 0.55 | 4.33 | 4.93 | 957,267.30 | 13.24 | 11.76 | 16.74 | 15.00 | 40.08 | 38.46 | 24.07 | 21.69 | 1.95 | -- | 0.1124 | 30.01 | 2.51 | 33.22 | 9.00 | 33.56 | 19.66 | 32.04 |
Data as of Jun 20 2024. Currency figures normalised to Sichuan Biokin Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
21.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 5.31m | 5.87% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 4.33m | 4.78% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 3.10m | 3.42% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 2.22m | 2.46% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 967.04k | 1.07% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 875.61k | 0.97% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 842.28k | 0.93% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 758.03k | 0.84% |
| Golden Eagle Asset Management Co., Ltd.as of 31 Dec 2023 | 541.95k | 0.60% |
| Baoying Fund Management Co., Ltd.as of 31 Dec 2023 | 506.07k | 0.56% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
